The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

This study aims to evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate‐to‐severe AD. In this randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300 mg) or placebo once every two weeks for 16 weeks and were followed up for 12 weeks. At week 16, 26·8% of patients in the dupilumab group and 4·8% of patients in the placebo group achieved the primary endpoint. Compared with placebo, higher proportions of patients However, the incidence of conjunctivitis, allergic conjunctivitis and injection site reaction was higher in the dupilumab group than in the placebo group. In adult Chinese patients, dupilumab effectively improved the signs and symptoms of AD and demonstrated a favourable safety profile.